

Atty. Dkt. No. 058333-0106

#7
3-27-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sunghoon Kim et al.

Title: IMMUNOLOGICAL ENHANCEMENT AGENT
COMPRISING N-TERMINAL PEPTIDE OF P43
AS AN EFFECTIVE COMPONENT

RECEIVED

NOV 26 2001

TECH CENTER 1600/2900

Appl. No.: 09/930,169

Filing Date: August 16, 2001

Examiner: Unassigned

Art Unit: 1646

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

The relevance of the documents is described in the present specification.

All of the documents are in English.


Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date November 21, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

By _____

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 058333-0106		SERIAL NO. 09/930,169	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Sunghoon Kim et al.			
				FILING DATE August 16, 2001		GROUP ART UNIT 1646	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A1	QUEVILLON, S. et al. "The p43 Component of the Mammalian Multi-synthetase Complex Is Likely to be the Precursor of the Endothelial Monocyte-activating Polypeptide II Cytokine", J.Biol.Chem. (1997), Vol. 272, No. 51, pp. 32573-32579, The American Society for Biochemistry and Molecular Biology, Inc.					
	A2	BEHRENSDORF, H. et al. "The endothelial monocyte-activating polypeptide II (EMAP II) is a substrate for caspase-7" FEBS Lett., (2000), Vol. 466, pp. 143-147, Federation of European Biochemical Societies.					
	A3	KAO, J. et al. "A Peptide Derived from the Amino Terminus of Endothelial-Monocyte-activating Polypeptide II Modulates Mononuclear and Polymorphonuclear Leukocyte Functions, Defines an Apparently Novel Cellular Interaction Site, and Induces an Acute Inflammatory Response", J. Biol. Chem. (1994), Vol. 269, No. 13, pp. 9774-9782, The American Society for Biochemistry and Molecular Biology, Inc.					
	A4	KAO, J. et al. "Endothelial Monocyte-activating Polypeptide II: A Novel Tumor-Derived Polypeptide That Activates Host-Response Mechanisms", J. Biol. Chem. (1992), Vol. 267, No. 28, pp. 20239-20247, The American Society for Biochemistry and Molecular Biology, Inc.					
	A5	KAO, J. et al. "Characterization of a Novel Tumor-derived Cytokine: Endothelial-Monocyte Activating", J. Biol. Chem. (1994), Vol. 269, No. 40, pp. 25106-25119, The American Society for Biochemistry and Molecular Biology, Inc.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 058333-0106	SERIAL NO. 09/930,169
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Sunghoon Kim et al.	
				FILING DATE August 16, 2001	GROUP ART UNIT 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A6	KNIES, U.E. et al., "Regulation of endothelial monocyte-activating polypeptide II release by apoptosis", Proc. Natl. Acad. Sci. USA (1998), Vol. 95, pp. 12322-12337.			
	A7	SCHWARZ, M.A. et al., "Endothelial-Monocyte Activating Polypeptide II, A Novel Antitumor Cytokine that Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells", J. Exp. Med. (1999) Vol. 190, No. 3, pp. 341-352, The Rockefeller University Press.			
	A8	TAS, M.P.R. and MURRAY, J.C., "Endothelial-Monocyte-Activating Polypeptide II", Int. J. Biochem. Cell. Biol. (1996), Vol. 28, No. 8, pp. 837-841, 1996 Elsevier Science Ltd.			
	A9	SCHLUESENER, H.J. et al., "Localization of Endothelial-Monocyte-Activating Polypeptide II (EMAP II), a Novel Proinflammatory Cytokine, to Lesions of Experimental Autoimmune Encephalomyelitis, Neuritis, and Uveitis", GLIA (1997), Vol. 20, pp. 365-372, Wiley-Liss, Inc.			
	A10	BERGER, A.C. et al., "Endothelial Monocyte-Activating Polypeptide II, a Tumor-Derived Cytokine That Plays an Important Role in Inflammation, Apoptosis, and Angiogenesis", J. Immunother. (2000), Vol. 23, No. 5, pp. 519-527, Lippincott, Williams and Wilkins, Inc.			
	A11	KO, Y.G. et al., "A Cofactor of tRNA Synthetase, p43, Is Secreted to Up-regulate Proinflammatory Genes", J. Biol. Chem. (2001), Vol. 276, No. 25, pp. 23028-23033, The American Society for Biochemistry and Molecular Biology, Inc.			
	A12	PARK, S.G. et al., "Precursor of Pro-apoptotic Cytokine Modulates Aminoacylation Activity of tRNA Synthetase", J. Biol. Chem. (1999), Vol. 274, No. 24, pp.16673-16676, The American Society for Biochemistry and Molecular Biology, Inc.			
EXAMINER			DATE CONSIDERED		
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					